ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial

Ebru Dirikgil, Jolijn R van Leeuwen, Obbo W Bredewold, Argho Ray, Jacqueline T Jonker, Darius Soonawala, Hilde H F Remmelts, Bastiaan van Dam, Willem Jan Bos, Cees van Kooten, Joris Rotmans, Ton Rabelink, Y K Onno Teng, Ebru Dirikgil, Jolijn R van Leeuwen, Obbo W Bredewold, Argho Ray, Jacqueline T Jonker, Darius Soonawala, Hilde H F Remmelts, Bastiaan van Dam, Willem Jan Bos, Cees van Kooten, Joris Rotmans, Ton Rabelink, Y K Onno Teng

Abstract

Introduction: Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies have shown that the effect on achieving (clinical) remission, frequency and severity of relapses is equivalent for both therapies, but there is accumulating data that the long-term safety profile of RTX might outperform CYC. Combination of RTX with low-dose CYC (LD-CYC) has been investigated in only a few uncontrolled cohort studies, in which clinical remission and a favourable immunological state with low relapse rates was quickly achieved. In this randomised controlled trial, we aim to investigate whether the combination treatment (RTX+LD CYC) is superior in comparison to standard care with RTX only.

Methods and analysis: This study is an open-label, multicentre, 1:1 randomised, prospective study for patients with AAV with generalised disease, defined as involvement of major organs, that is, kidneys, lungs, heart and nervous system. In total, 100 patients will be randomised 1:1 to receive either remission induction therapy with standard of care (RTX) or combination treatment (RTX+LD CYC) in addition to steroids and both arms are followed by maintenance with RTX retreatments (tailored to B-cell and ANCA status). Our primary outcome is the number of retreatments needed to maintain clinical remission over 2 years. Secondary outcomes are relevant clinical endpoints, safety, quality of life and immunological responses.

Ethics and dissemination: This study has received approval of the Medical Ethics Committee of the Leiden University Medical Center (P18.216, NL67515.058.18, date: 7 March 2019). The results of this trial (positive and negative) will be submitted for publication in relevant peer-reviewed publications and the key findings presented at national and international conferences.

Trial registration number: NCT03942887.

Keywords: Clinical trials; Glomerulonephritis; IMMUNOLOGY; Nephrology; RHEUMATOLOGY.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Schematic representation of the study treatment schedule. ANCA, antineutrophil cytoplasmic antibody; CYC, cyclophosphamide; MP, methylprednisolone; neg, negative; pos, positive; pred, prednisolone; RTX, rituximab; w, weeks.

References

    1. Ntatsaki E, Carruthers D, Chakravarty K, et al. . BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology 2014;53:2306–9. 10.1093/rheumatology/ket445
    1. Yates M, Watts RA, Bajema IM, et al. . EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75:1583–94. 10.1136/annrheumdis-2016-209133
    1. Rovin BH, Adler SG, Barratt J, et al. . Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 2021;100:753–79. 10.1016/j.kint.2021.05.015
    1. Specks U, Merkel PA, Seo P, et al. . Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:417–27. 10.1056/NEJMoa1213277
    1. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 2014;10:463–73. 10.1038/nrrheum.2014.103
    1. Stone JH, Merkel PA, Spiera R, et al. . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–32. 10.1056/NEJMoa0909905
    1. Jones RB, Tervaert JWC, Hauser T, et al. . Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211–20. 10.1056/NEJMoa0909169
    1. Jones RB, Furuta S, Tervaert JWC, et al. . Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 2015;74:1178–82. 10.1136/annrheumdis-2014-206404
    1. Dirikgil E, Jonker JT, Tas SW, et al. . Clinical practice audit on the management of antineutrophil cytoplasmic antibody-associated vasculitis in the Netherlands. Kidney Int Rep 2021;6:2671–8. 10.1016/j.ekir.2021.08.002
    1. Smith RM, Jones RB, Specks U, et al. . Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 2020;79:1243–9. 10.1136/annrheumdis-2019-216863
    1. van Daalen EE, Rizzo R, Kronbichler A, et al. . Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis 2017;76:1064–9. 10.1136/annrheumdis-2016-209925
    1. Chung SA, Langford CA, Maz M, et al. . 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2021;73:1366–83. 10.1002/art.41773
    1. McAdoo SP, Medjeral-Thomas N, Gopaluni S, et al. . Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant 2019;34:63–73. 10.1093/ndt/gfx378
    1. Cortazar FB, Muhsin SA, Pendergraft WF, et al. . Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis. Kidney Int Rep 2018;3:394–402. 10.1016/j.ekir.2017.11.004
    1. Pepper RJ, McAdoo SP, Moran SM, et al. . A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 2019;58:260–8. 10.1093/rheumatology/key288
    1. de Groot K, Harper L, Jayne DRW, et al. . Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670–80. 10.7326/0003-4819-150-10-200905190-00004
    1. Smith RM, Jones RB, Guerry M-J, et al. . Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:3760–9. 10.1002/art.34583
    1. Fussner LA, Hummel AM, Schroeder DR, et al. . Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol 2016;68:1700–10. 10.1002/art.39637
    1. Morgan MD, Szeto M, Walsh M, et al. . Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther 2017;19:129. 10.1186/s13075-017-1321-1
    1. Kemna MJ, Damoiseaux J, Austen J, et al. . ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 2015;26:537–42. 10.1681/ASN.2013111233
    1. Guillevin L, Pagnoux C, Karras A, et al. . Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771–80. 10.1056/NEJMoa1404231
    1. Terrier B, Pagnoux C, Perrodeau Élodie, et al. . Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 2018;77:1150–6. 10.1136/annrheumdis-2017-212768
    1. Charles P, Terrier B, Perrodeau Élodie, et al. . Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 2018;77:1143–9. 10.1136/annrheumdis-2017-212878
    1. Smith RJD, Merkel P. A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease [abstract], 2019. Available:
    1. Hiepe F, Radbruch A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol 2016;12:232–40. 10.1038/nrneph.2016.20
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group . KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021;99:S1–87. 10.1016/j.kint.2020.11.003
    1. van Dam LS, Dirikgil E, Bredewold EW, et al. . PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab. Nephrol Dial Transplant 2021;36:1408–17. 10.1093/ndt/gfaa066

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere